NCT04386512

Brief Summary

The main objective of this retrospective clinical epidemiology study is to describe the characteristics of Covid-19 cases requiring hospitalization in adult patients with lymphomas during the initial phase of the epidemic (from 01/03/20 to 30/04/20). The specific objectives are to estimate the frequency of severe forms of Covid-19 and those requiring intensive care hospitalisation, as well as the mortality related to the epidemic among the active file of patients followed for lymphoma at each study site, to investigate whether certain chemotherapy and/or immunotherapy treatments seem to be associated with severe forms or prolonged evolutions of Covid-19, to describe possible atypical clinical forms among the population of patients treated for lymphoma. Translated with www.DeepL.com/Translator (free version)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
89

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 13, 2020

Completed
2 days until next milestone

Study Start

First participant enrolled

May 15, 2020

Completed
17 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2020

Completed
Last Updated

August 7, 2020

Status Verified

August 1, 2020

Enrollment Period

17 days

First QC Date

May 12, 2020

Last Update Submit

August 6, 2020

Conditions

COVIDLymphoma

Keywords

covidlymphomaepidemiology

Outcome Measures

Primary Outcomes (2)

  • mortality

    2 months

  • transfer to ICU

    2 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a current or past history of lymphoma who were hospitalized with Covid-19 infection between March the 1st and April the 30th in ile de France or Est region in France

You may qualify if:

  • Patients at least 18 years of age with lymphoma and a diagnosis of Covid-19 requiring hospitalization.
  • In order not to bias the data by excluding patients with adverse outcomes, we will also collect data from deceased patients.

You may not qualify if:

  • Patients who refused to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CH de Versailles

Le Chesnay, France

Location

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
investigator MD

Study Record Dates

First Submitted

May 12, 2020

First Posted

May 13, 2020

Study Start

May 15, 2020

Primary Completion

June 1, 2020

Study Completion

July 15, 2020

Last Updated

August 7, 2020

Record last verified: 2020-08

Locations

FR(1)